Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026)

Protalix BioTherapeutics has reported Accounts Payables for 17 years, with the latest figure at $6.5 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 2.74% year-over-year to $6.5 million in Q2 2026; TTM through Jun 2026 was $6.5 million, a 2.74% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 16.02% from the prior year.
• Accounts Payables was $6.5 million for Q2 2026 at Protalix BioTherapeutics, up from $4.3 million in the prior quarter.
• The five-year high for Accounts Payables was $19.6 million in Q3 2024, with the low at $4.1 million in Q1 2025.
• Average Accounts Payables over 5 years is $11.2 million, with a median of $12.5 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 46.45% in 2023, then tumbled 78.04% in 2025.
• Over 5 years, Accounts Payables stood at $12.3 million in 2022, then tumbled by 64.8% to $4.3 million in 2023, then climbed by 4.93% to $4.5 million in 2024, then increased by 16.02% to $5.3 million in 2025, then advanced by 23.71% to $6.5 million in 2026.
• The last three Accounts Payables figures came in at $6.5 million (Q2 2026), $4.3 million (Q1 2026), and $5.3 million (Q4 2025), per Business Quant data.